<DOC>
	<DOCNO>NCT01080391</DOCNO>
	<brief_summary>To compare progression-free survival subject relapse multiple myeloma receive CRd v subject receive Rd randomize multicenter setting .</brief_summary>
	<brief_title>Phase 3 Study Comparing Carfilzomib , Lenalidomide , Dexamethasone ( CRd ) v Lenalidomide Dexamethasone ( Rd ) Subjects With Relapsed Multiple Myeloma</brief_title>
	<detailed_description>This Phase 3 , randomize , open-label , multicenter study compare two treatment regimen subject relapse multiple myeloma . Eligible subject randomize 1:1 ratio receive either control Rd CRd . Randomization stratify β2 microglobulin level ( &lt; v ≥ 2.5 mg/L ) , prior bortezomib ( vs yes ) , prior lenalidomide ( vs yes ) . Subjects receive treatment determine randomization 28-day cycle disease progression unacceptable toxicity ( whichever occurs first ) . The primary endpoint Phase 3 study progression-free survival .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Symptomatic multiple myeloma 2 . Measurable disease , define one following ( assess within 21 day prior randomization ) : Serum Mprotein ≥ 0.5 g/dL Urine BenceJones protein ≥ 200 mg/24 hour For IgA patient whose disease reliably measure serum quantitative immunoglobulin ( qIgA ) ≥ 750 mg/dL ( 0.75 g/dL ) 3 . Prior treatment least one , three , regimens multiple myeloma 4 . Documented relapse progressive disease regimen 5 . Achieved response least one prior regimen 6 . Age ≥ 18 year 7 . Life expectancy ≥ 3 month 8 . Eastern Cooperative Oncology Group performance status 02 9 . Adequate hepatic function , serum ALT ≤ 3.5 time upper limit normal serum direct bilirubin ≤ 2 mg/dL ( 34 µmol/L ) within 21 day prior randomization 10 . Absolute neutrophil count ≥ 1.0 × 10^9/L within 21 day prior randomization 11 . Hemoglobin ≥ 8 g/dL ( 80 g/L ) within 21 day prior randomization 12 . Platelet count ≥ 50 × 10^9/L ( ≥ 30 × 10^9/L myeloma involvement bone marrow &gt; 50 % ) within 21 day prior randomization 13 . Creatinine clearance ( CrCl ) ≥ 50 mL/minute within 21 day prior randomization 14 . Written inform consent accordance federal , local , institutional guideline 15 . Females childbearing potential must agree ongoing pregnancy test practice contraception 16 . Male subject must agree practice contraception 1 . If previously treat bortezomib ( alone combination ) , progression treatment 2 . If previously treat lenalidomide dexamethasone ( len/dex ) combination : Progression first 3 month initiate treatment Any progression treatment len/dex combination subject 's recent line therapy 3 . Discontinuation previous lenalidomide dexamethasone due intolerance ; subject intolerant bortezomib exclude 4 . Prior carfilzomib treatment 5 . POEMS syndrome ( polyneuropathy , organomegaly , endocrinopathy , monoclonal protein , skin change ) 6 . Waldenström 's macroglobulinemia IgM myeloma 7 . Plasma cell leukemia ( &gt; 2.0 × 10^9/L circulate plasma cell standard differential ) 8 . Chemotherapy investigational agent within 3 week prior randomization antibody therapy within 6 week prior randomization 9 . Radiotherapy multiple site immunotherapy/antibody therapy within 28 day prior randomization ; localize radiotherapy single site within 7 day prior randomization 10 . Corticosteroid therapy dose equivalent dexamethasone &gt; 4 mg/day within 21 day prior randomization 11 . Pregnant lactating female 12 . Major surgery within 21 day prior randomization 13 . Acute active infection require treatment ( systemic antibiotic , antiviral , antifungal ) within 14 day prior randomization 14 . Known human immunodeficiency virus infection 15 . Active hepatitis B C infection 16 . Myocardial infarction within 4 month prior randomization , NYHA Class III IV heart failure , uncontrolled angina , history severe coronary artery disease , severe uncontrolled ventricular arrhythmia , sick sinus syndrome , electrocardiographic evidence acute ischemia Grade 3 conduction system abnormalities unless subject pacemaker 17 . Uncontrolled hypertension uncontrolled diabetes within 14 day prior randomization 18 . Other malignancy , include MDS , within past 3 year exception ) adequately treat basal cell carcinoma , squamous cell skin cancer , thyroid cancer ; b ) carcinoma situ cervix breast ; c ) prostate cancer Gleason Grade 6 less stable prostatespecific antigen level ; ) cancer consider cure surgical resection unlikely impact survival duration study , localize transitional cell carcinoma bladder benign tumor adrenal pancreas 19 . Significant neuropathy ( Grades 34 , Grade 2 pain ) within 14 day prior randomization 20 . Known history allergy Captisol® ( cyclodextrin derivative use solubilize carfilzomib ) 21 . Contraindication require concomitant drug supportive treatment , include hypersensitivity anticoagulation antiplatelet option , antiviral drug , intolerance hydration due preexist pulmonary cardiac impairment 22 . Ongoing graftvshost disease 23 . Subjects pleural effusion require thoracentesis ascites require paracentesis within 14 day prior randomization 24 . Any clinically significant medical disease condition , Investigator 's opinion , may interfere protocol adherence subject 's ability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
</DOC>